<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">486812</article-id><article-id pub-id-type="doi">10.23868/gc486812</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Analysis of the activities of cord blood banks in the Russian Federation</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ деятельности банков пуповинной крови в Российской Федерации</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5608-1925</contrib-id><contrib-id contrib-id-type="spin">9490-7519</contrib-id><name-alternatives><name xml:lang="en"><surname>Tyumina</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Тюмина</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>centr123@bk.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2569-9394</contrib-id><contrib-id contrib-id-type="spin">6990-2040</contrib-id><name-alternatives><name xml:lang="en"><surname>Volchkov</surname><given-names>Stanislav E.</given-names></name><name xml:lang="ru"><surname>Волчков</surname><given-names>Станислав Евгеньевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>quality@cordbank.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-4227-7593</contrib-id><contrib-id contrib-id-type="spin">5723-3049</contrib-id><name-alternatives><name xml:lang="en"><surname>Ovchinnikov</surname><given-names>Pavel A.</given-names></name><name xml:lang="ru"><surname>Овчинников</surname><given-names>Павел Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ovchinnikov@cordbank.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-5892-7152</contrib-id><name-alternatives><name xml:lang="en"><surname>Bugakov</surname><given-names>Alexander I.</given-names></name><name xml:lang="ru"><surname>Бугаков</surname><given-names>Александр Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>bugakow@cordbank.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-5138-8495</contrib-id><contrib-id contrib-id-type="spin">6609-2143</contrib-id><name-alternatives><name xml:lang="en"><surname>Porapov</surname><given-names>Ivan V.</given-names></name><name xml:lang="ru"><surname>Потапов</surname><given-names>Иван Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>ivp@gemabank.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="spin">5076-9801</contrib-id><name-alternatives><name xml:lang="en"><surname>Prihodko</surname><given-names>Aleksandr V.</given-names></name><name xml:lang="ru"><surname>Приходько</surname><given-names>Александр Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.</p></bio><bio xml:lang="ru"><p>д.м.н.</p></bio><email>vp@gemabank.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5049-1368</contrib-id><name-alternatives><name xml:lang="en"><surname>Prihodko</surname><given-names>Egor M.</given-names></name><name xml:lang="ru"><surname>Приходько</surname><given-names>Егор Михайлович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ceo@pokrovcell.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-4044-8215</contrib-id><name-alternatives><name xml:lang="en"><surname>Komarova</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Комарова</surname><given-names>Ольга Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>o.kom1909@yandex.ru</email><xref ref-type="aff" rid="aff5"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Samara Regional Medical Center Dinasty</institution></aff><aff><institution xml:lang="ru">Самарский областной медицинский центр Династия</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Samara State Medical University</institution></aff><aff><institution xml:lang="ru">Самарский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">“IMCB” PJSC</institution></aff><aff><institution xml:lang="ru">ПАО «ММЦБ»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">LLC Pokrovskya Bank Stem Cells</institution></aff><aff><institution xml:lang="ru">ООО «Покровский банк стволовых клеток»</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Orenburg Transfusion Blood Station</institution></aff><aff><institution xml:lang="ru">Оренбургская станция переливания крови</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-08-22" publication-format="electronic"><day>22</day><month>08</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-10-03" publication-format="electronic"><day>03</day><month>10</month><year>2023</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>205</fpage><lpage>218</lpage><history><date date-type="received" iso-8601-date="2023-06-08"><day>08</day><month>06</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-07-27"><day>27</day><month>07</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-Вектор</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2026-10-03"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/486812">https://genescells.ru/2313-1829/article/view/486812</self-uri><abstract xml:lang="en"><p>This review aimed to analyze the activities of all state and commercial cord blood banks in the Russian Federation, to estimate the total number of cord blood samples in storage at the beginning of 2023, and to determine the practical use of the biomaterial for treatment — allogeneic and autologous transplants for oncohematological diseases, as well as for scientific research in the field of regenerative medicine for the entire period of the banks' operation, which is twenty years.</p> <p>To date, there are 12 cord blood banks providing personal, public or mixed storage of samples. At the moment, up to 26,000 cord blood samples are in public storage, and about 75,000 samples are in personal storage.</p> <p>As part of the review, the main and additional services provided by banks, as well as their current cost, were studied. The average cost of cord blood sample collection in the Russian Federation is 62,500 rubles, and the average annual cost of storage is 6,000 rubles. The main market indicators, trends, key problems of biobanking and prospects for the use of cord blood cells in the Russian Federation in the coming years are considered in detail.</p> <p>Separately, data on the prospects for the use of umbilical cord mesenchymal stem cells, a widely studied biomaterial, which, like cord blood, can be collected after childbirth and cryopreserved for long-term storage, are briefly presented. Stem cells of the umbilical cord are being actively studied in the field of regenerative medicine due to their properties to restore cartilaginous muscle and bone tissue, stimulate the growth of new blood vessels, and block autoimmune reactions.</p> <p>In addition, the current tasks and results of the activities of Ruscord, an association of specialists and organizations in the field of procurement, storage, use of cord blood cells and cell technologies, which over several years of its activity has already made a significant contribution to the development of the biobanking market, were analyzed. In September 2020, a unified standard for the collection, processing, storage and issuance of cord blood for use was approved — the Russian standard RUSCORD.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре проанализирована деятельность всех государственных и коммерческих банков пуповинной крови в Российской Федерации, выполнена оценка общего количества образцов пуповинной крови на хранении на начало 2023 года, а также определено практическое использование биоматериала для лечения (аллогенных и аутологичных трансплантаций при онкогематологических заболеваниях) и научно-исследовательской работы в области регенеративной медицины за весь период работы банков, составляющий двадцать лет.</p> <p>На сегодняшний день в Российской Федерации насчитывается 12 банков пуповинной крови, выполняющих персональное, публичное или смешанное хранение образцов. На данный момент на публичном хранении находится до 26 тыс. образов пуповинной крови, а на персональном хранении — около 75 тыс. образцов.</p> <p>В рамках обзора изучены основные и дополнительные услуги, предоставляемые банками, а также их актуальная стоимость: средняя стоимость заготовки образца пуповинной крови в Российской Федерации составляет 62 500 руб., а средняя годовая стоимость хранения — 6000 руб. Подробно рассмотрены основные показатели рынка, тенденции, ключевые проблемы биобанкирования и перспективы применения клеток пуповинной крови в Российской Федерации в ближайшие годы.</p> <p>Отдельно кратко представлены данные о перспективах применения мезенхимальных стволовых клеток пупочного канатика — широко изучаемого биоматериала, который, как и пуповинную кровь, можно собрать после родов и криоконсервировать для длительного хранения. Стволовые клетки пупочного канатика активно изучаются в регенеративной медицине благодаря их свойствам восстанавливать хрящевую, мышечную, костную ткань, стимулировать рост новых кровеносных сосудов, блокировать аутоиммунные реакции.</p> <p>Дополнительно проанализированы актуальные задачи и результаты деятельности ассоциации специалистов и организаций в области заготовки, хранения, применения клеток пуповинной крови и клеточных технологий «Рускорд», которая за несколько лет своей работы уже внесла существенный вклад в развитие рынка биобанкирования: в сентябре 2020 года утверждён единый стандарт сбора, процессинга, хранения и выдачи пуповинной крови для применения — российский стандарт RUSCORD.</p></trans-abstract><kwd-group xml:lang="en"><kwd>umbilical cord blood</kwd><kwd>cord blood bank</kwd><kwd>transplantation</kwd><kwd>hematopoietic stem cells</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пуповинная кровь</kwd><kwd>банк пуповинной крови</kwd><kwd>трансплантация</kwd><kwd>гемопоэтические стволовые клетки</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconis anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174–1184. doi: 10.1056/NEJM198910263211707</mixed-citation><mixed-citation xml:lang="ru">Gluckman E., Broxmeyer H.A., Auerbach A.D., et al. Hematopoietic reconstitution in a patient with Fanconis anemia by means of umbilical-cord blood from an HLA-identical sibling // N Engl J Med. 1989. Vol. 321, N 17. P. 1174–1184. doi: 10.1056/NEJM198910263211707</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045–1053. doi: 10.3324/haematol.2021.279189</mixed-citation><mixed-citation xml:lang="ru">Niederwieser D., Baldomero H., Bazuaye N., et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors // Haematologica. 2022. Vol. 107, N 5. P. 1045–1053. doi: 10.3324/haematol.2021.279189</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Dumont-Lagacé M, Feghaly A, Meunier MC, et al. UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities. Transplant Cell Ther. 2022;28(7):410.e1–410.e5. doi: 10.1016/j.jtct.2022.03.016</mixed-citation><mixed-citation xml:lang="ru">Dumont-Lagacé M., Feghaly A., Meunier M.C., et al. UM171 expansion of cord blood improves donor availability and HLA matching for all patients, including minorities // Transplant Cell Ther. 2022. Vol. 28, N 7. P. 410.e1–410.e5. doi: 10.1016/j.jtct.2022.03.016</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.rdkm.rusfond.ru/ [Internet]. Aktivacija donora: chto pochem v donorskih registrah — nashem Nacional’nom i inostrannyh. Available from: https://rdkm.rusfond.ru/registr/059 (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.rdkm.rusfond.ru/ [интернет]. Активация донора: что почем в донорских регистрах — нашем Национальном и иностранных. Доступ по ссылке: https://rdkm.rusfond.ru/registr/059</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.asi.org.ru/ [Internet]. Kak stat’ donorom kostnogo mozga i zachem jeto nuzhno. Agentstvo social’noj informacii. Available from: https://www.asi.org.ru/2018/10/29/kakstatdonoro/ (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.asi.org.ru/ [интернет]. Как стать донором костного мозга и зачем это нужно. Агентство социальной информации. Доступ по ссылке: https://www.asi.org.ru/2018/10/29/kakstatdonoro/</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021;138(16):1429–1440. doi: 10.1182/blood.2021011719</mixed-citation><mixed-citation xml:lang="ru">Horwitz M.E., Stiff P.J., Cutler C., et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study // Blood. 2021. Vol. 138, N 16. P. 1429–1440. doi: 10.1182/blood.2021011719</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Wagner JE Jr, Brunstein CG, Boitano AE, et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell. 2015;18(1):144–155. doi: 10.1016/j.stem.2015.10.004</mixed-citation><mixed-citation xml:lang="ru">Wagner J.E. Jr., Brunstein C.G., Boitano A.E., et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft // Cell Stem Cell. 2015. Vol. 18, N 1. P. 144–155. doi: 10.1016/j.stem.2015.10.004</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.fda.gov/ [Internet]. FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cel</mixed-citation><mixed-citation xml:lang="ru">https://www.fda.gov/ [Internet]. FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. Доступ по ссылке: https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cel</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.gamida-cell.com/ [Internet]. Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) receives FDA approval. Available from: https://statistics.wmda.info/ https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cells-allogeneic-cell-therapy-omisirger</mixed-citation><mixed-citation xml:lang="ru">https://www.gamida-cell.com/ [Internet]. Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) receives FDA approval. Доступ по ссылке: https://statistics.wmda.info/ https://investors.gamida-cell.com/news-events/press-releases/news-release-details/gamida-cells-allogeneic-cell-therapy-omisirger</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">https://statistics.wmda.info/ [Internet]. WMDA. Total Number of Donors and Cord blood units. Available from: https://statistics.wmda.info/</mixed-citation><mixed-citation xml:lang="ru">https://statistics.wmda.info/ [Internet]. WMDA. Total Number of Donors and Cord blood units. Доступ по ссылке: https://statistics.wmda.info/</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. https://www.researchandmarkets.com/ [Internet]. Stem Cell/Cord Blood Banking Global Market Report 2023. Available from: https://www.researchandmarkets.com/reports/5735457/stem-cellcord-blood-banking-global-market-report</mixed-citation><mixed-citation xml:lang="ru">https://www.researchandmarkets.com/ [Internet]. Stem Cell/Cord Blood Banking Global Market Report 2023. Доступ по ссылке: https://www.researchandmarkets.com/reports/5735457/stem-cellcord-blood-banking-global-market-report</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Litvinova LS, Goncharov AG, Shupletsova VV, et al. Analysis of the legal regulation of the circulation of cord blood and its components in the Russian Federation and abroad. Genes and cells. 2020;15(4):88–94. (In Russ). doi: 10.23868/202012014</mixed-citation><mixed-citation xml:lang="ru">Литвинова Л.С., Гончаров А.Г., Шуплецова В.В., и др. Анализ правового регулирования обращения пуповинной крови и ее компонентов в Российской Федерации и за рубежом // Гены и клетки. 2020. Т. 15, N 4. С. 88–94. doi: 10.23868/202012014</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.publication.pravo.gov.ru/ [Internet]. Order of the Ministry of Health of the Russian Federation dated December 12, 2018 No. 875n “Ob utverzhdenii Porjadka okazanija medicinskoj pomoshhi pri zabolevanijah (sostojanijah), dlja lechenija kotoryh primenjaetsja transplantacija (peresadka) kostnogo mozga i gemopojeticheskih stvolovyh kletok i vnesenii izmenenija v Porjadok okazanija medicinskoj pomoshhi po profilju “hirurgija (transplantacija organov i (ili) tkanej cheloveka)””. Available from: http://publication.pravo.gov.ru/Document/View/0001201901090037 (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.publication.pravo.gov.ru/ [интернет]. Приказ Министерства здравоохранения Российской Федерации от 12.12.2018 № 875н «Об утверждении Порядка оказания медицинской помощи при заболеваниях (состояниях), для лечения которых применяется трансплантация (пересадка) костного мозга и гемопоэтических стволовых клеток и внесении изменения в Порядок оказания медицинской помощи по профилю “хирургия (трансплантация органов и (или) тканей человека)”». Доступ по ссылке: http://publication.pravo.gov.ru/Document/View/0001201901090037</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Tjumina OV, Hurcilava OG, Smoljaninov AB. Pupovinnaja krov’: zagotovka, hranenie, transplantacija i regenerativnaja medicina. Saint Petersburg: Sintez Buk, Nauka; 2012. 352 p. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Тюмина О.В., Хурцилава О.Г., Смолянинов А.Б. Пуповинная кровь: заготовка, хранение, трансплантация и регенеративная медицина. Санкт-Петербург : Синтез Бук, Наука, 2012. 352 с.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.gemabank.ru/ [Internet]. Available from: https://gemabank.ru/predstaviteli (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.gemabank.ru/ [интернет]. Роддома и перинатальные центры. Доступ по ссылке: https://gemabank.ru/predstaviteli</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.gemabank.ru/ [Internet]. Publichnoe akcionernoe obshhestvo «Mezhdunarodnyj Medicinskij Centr Obrabotki i Kriohranenija Biomaterialov» (PAO «MMCB»), godovoj otchet po itogam 2020 goda. Moskva, 2021. Available from: https://invest.gemabank.ru/download/issuer_report/Annual_report_20.pdf (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.gemabank.ru/ [интернет]. Публичное акционерное общество «Международный Медицинский Центр Обработки и Криохранения Биоматериалов» (ПАО «ММЦБ»), годовой отчет по итогам 2020 года. Москва, 2021. Доступ по ссылке: https://invest.gemabank.ru/download/issuer_report/Annual_report_20.pdf</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.viacord.com/ [Internet]. ViaCORD: Consumer CB Use Summary. Available from: https://www.viacord.com/Images/Consumer%20CB%20Use%20Summary%20-%20Over%20500-0920_tcm117-230237.pdf</mixed-citation><mixed-citation xml:lang="ru">https://www.viacord.com/ [Internet]. ViaCORD: Consumer CB Use Summary. Доступ по ссылке: https://www.viacord.com/Images/Consumer%20CB%20Use%20Summary%20-%20Over%20500-0920_tcm117-230237.pdf</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Ulus AT, Mungan C, Kurtoglu M, et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART trial). Int J Stem Cells. 2020;13(3):364–376. doi: 10.15283/ijsc20075</mixed-citation><mixed-citation xml:lang="ru">Ulus A.T., Mungan C., Kurtoglu M., et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART trial) // Int J Stem Cells. 2020. Vol. 13, N 3. P. 364–376. doi: 10.15283/ijsc20075</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Kahraman NS, Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial. Int J Ophthalmol. 2020;13(9):1423–1429. doi: 10.18240/ijo.2020.09.14</mixed-citation><mixed-citation xml:lang="ru">Kahraman N.S., Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial // Int J Ophthalmol. 2020. Vol. 13, N 9. P. 1423–1429. doi: 10.18240/ijo.2020.09.14</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang J, Lv S, Liu X, et al. Umbilical cord mesenchymal stem cell treatment for crohn’s disease: a randomized controlled clinical trial. Gut Liver. 2018;12(1):73–78. doi: 10.5009/gnl17035</mixed-citation><mixed-citation xml:lang="ru">Zhang J., Lv S., Liu X., et al. Umbilical cord mesenchymal stem cell treatment for crohn’s disease: a randomized controlled clinical trial // Gut Liver. 2018. Vol. 12, N 1. P. 73–78. doi: 10.5009/gnl17035</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Wang L, Huang S, Li S, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther. 2019;13:4331–4340. doi: 10.2147/DDDT.S225613</mixed-citation><mixed-citation xml:lang="ru">Wang L., Huang S., Li S., et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study // Drug Des Devel Ther. 2019. Vol. 13. P. 4331–4340. doi: 10.2147/DDDT.S225613</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Jia Y, Shu X, Yang X, et al. Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis. Stem Cell Res Ther. 2020;11(1):277. doi: 10.1186/s13287-020-01787-4</mixed-citation><mixed-citation xml:lang="ru">Jia Y., Shu X., Yang X., et al. Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis // Stem Cell Res Ther. 2020. Vol. 11, N 1. P. 277. doi: 10.1186/s13287-020-01787-4</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl. Med. 2021;10(5):660–673. doi: 10.1002/sctm.20-0472</mixed-citation><mixed-citation xml:lang="ru">Lanzoni G., Linetsky E., Correa D., et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial // Stem Cells Transl Med. 2021. Vol. 10, N 5. P. 660–673. doi: 10.1002/sctm.20-0472</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Carlsson PO, Espes D, Sisay S, et al. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I/II randomised double-blind placebo-controlled trial. Diabetologia. 2023;66(8):1431–1441. doi: 10.1007/s00125-023-05934-3</mixed-citation><mixed-citation xml:lang="ru">Carlsson P.O., Espes D., Sisay S., et al. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a phase I/II randomised double-blind placebo-controlled trial // Diabetologia. 2023. Vol. 66, N 8. P. 1431–1441. doi: 10.1007/s00125-023-05934-3</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Zang L, Li Y, Hao H, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022;13(1):180. doi: 10.1186/s13287-022-02848-6</mixed-citation><mixed-citation xml:lang="ru">Zang L., Li Y., Hao H., et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial // Stem Cell Res Ther. 2022. Vol. 13, N 1. P. 180. doi: 10.1186/s13287-022-02848-6</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang С, Huang L, Wang X, et al. Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up. Stem Cell Res Ther. 2022;13(1):451–465. doi: 10.1186/s13287-022-03143-0</mixed-citation><mixed-citation xml:lang="ru">Zhang С., Huang L., Wang X., et al. Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up // Stem Cell Res Ther. 2022. Vol. 13, N 1. P. 451–465. doi: 10.1186/s13287-022-03143-0</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Petrou P, Yael G, Zohar A, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis. Neurololy. 2016;73(3):337–344. doi: 10.1001/jamaneurol.2015.4321</mixed-citation><mixed-citation xml:lang="ru">Petrou P., Yael G., Zohar A., et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis // JAMA Neurol. 2016. Vol. 73, N 3. P. 337–344. doi: 10.1001/jamaneurol.2015.4321</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Master YL, Wei-Meng Tian B, Xing-Fang Jin M, et al. A clinical research of 11cases of human umbilical cord mesenchymal stem cells for curing senile vascular dementia. Transpl Immunol. 2022;74:101669. doi: 10.1016/j.trim.2022.101669</mixed-citation><mixed-citation xml:lang="ru">Master Y.L., Wei-Meng Tian B., Xing-Fang Jin M., et al. A clinical research of 11cases of human umbilical cord mesenchymal stem cells for curing senile vascular dementia // Transpl Immunol. 2022. Vol. 74. P. 101669. doi: 10.1016/j.trim.2022.101669</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Świątkowska-Flis B, Zdolińska-Malinowska I, Sługocka D, et al. The use of umbilical cord-derived mesenchymal stem cells in patients with muscular dystrophies: results from compassionate use in real-life settings. Stem Cells Transl Med. 2021;10(10):1372–1383. doi: 10.1002/sctm.21-0027</mixed-citation><mixed-citation xml:lang="ru">Świątkowska-Flis B., Zdolińska-Malinowska I., Sługocka D., et al. The use of umbilical cord-derived mesenchymal stem cells in patients with muscular dystrophies: results from compassionate use in real-life settings // Stem Cells Transl Med. 2021. Vol. 10, N 10. P. 1372–1383. doi: 10.1002/sctm.21-0027</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Gu J, Huang L, Zhang C, et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Res Ther. 2020;3(11):43–53. doi: 10.1186/s13287-019-1545-x</mixed-citation><mixed-citation xml:lang="ru">Gu J., Huang L., Zhang C., et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial // Stem Cell Res Ther. 2020. Vol. 3, N 11. P. 43–53. doi: 10.1186/s13287-019-1545-x</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Sun JM, Dawson G, Franz L, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem Cells Transl Med. 2020;9(10):1137–1146. doi: 10.1002/sctm.19-0434</mixed-citation><mixed-citation xml:lang="ru">Sun J.M., Dawson G., Franz L., et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder // Stem Cells Transl Med. 2020. Vol. 9, N 10. P. 1137–1146. doi: 10.1002/sctm.19-0434</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Lan X, Sun Z, Chu C, et al. Dental pulp stem cells: an attractive alternative for cell therapy in ischemic stroke. Front Neurol. 2019;10:824–834. doi: 10.3389/fneur.2019.00824</mixed-citation><mixed-citation xml:lang="ru">Lan X., Sun Z., Chu C., et al. Dental pulp stem cells: an attractive alternative for cell therapy in ischemic stroke // Front Neurol. 2019. Vol. 10. P. 824. doi: 10.3389/fneur.2019.00824</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.ruscord.com/ [Internet]. Associacija Ruskord otkryvaet novuju vehu standartizacii dlja bankov pupovinnoj krovi v Rossii. Available from: https://ruscord.com/bez-kategorii/assocziacziya-ruskord-otkryvaet-novuyu-vehu-standartizaczii-dlya-bankov-pupovinnoj-krovi-v-rossii/ (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.ruscord.com/ [интернет]. Ассоциация Рускорд открывает новую веху стандартизации для банков пуповинной крови в России. Доступ по ссылке: https://ruscord.com/bez-kategorii/assocziacziya-ruskord-otkryvaet-novuyu-vehu-standartizaczii-dlya-bankov-pupovinnoj-krovi-v-rossii/</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.rosstat.gov.ru/ [Internet]. Rosstat predstavljaet pervuju ocenku VVP za 2022 god. Available from: https://rosstat.gov.ru/folder/313/document/198546 (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.rosstat.gov.ru/ [интернет]. Росстат представляет первую оценку ВВП за 2022 год. Доступ по ссылке: https://rosstat.gov.ru/folder/313/document/198546</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">https://www.rosstat.gov.ru/ [Internet]. Rosstat predstavljaet dannye o estestvennom dvizhenii naselenija v mae 2023 goda. Available from: https://rosstat.gov.ru/folder/313/document/212114 (In Russ).</mixed-citation><mixed-citation xml:lang="ru">https://www.rosstat.gov.ru/ [интернет]. Росстат представляет данные о естественном движении населения в мае 2023 года. Доступ по ссылке: https://rosstat.gov.ru/folder/313/document/212114</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Crompton K, Godler DE, Ling L, et al. Umbilical cord blood cell clearance post-infusion in immune-competent children with cerebral palsy. Cells Tissues Organs. 2022;10:1–8. doi: 10.1159/000527612</mixed-citation><mixed-citation xml:lang="ru">Crompton K., Godler D.E., Ling L., et al. Umbilical cord blood cell clearance post-infusion in immune-competent children with cerebral palsy // Cells Tissues Organs. 2022. Vol. 10. P. 1–8. doi: 10.1159/000527612</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Carpenter KLH, Major S, Tallman C, et al. White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism. Stem Cells Transl Med. 2019;8(2):138–147. doi: 10.1002/sctm.18-0251</mixed-citation><mixed-citation xml:lang="ru">Carpenter K.L.H., Major S., Tallman C., et al. White matter tract changes associated with clinical improvement in an open-label trial assessing autologous umbilical cord blood for treatment of young children with autism // Stem Cells Transl Med. 2019. Vol. 8, N 2. P. 138–147. doi: 10.1002/sctm.18-0251</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Laskowitz DT, Bennett ER, Durham RJ, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase I safety study. Stem Cells Transl Med. 2018;7(7):521–529. doi: 10.1002/sctm.18-0008</mixed-citation><mixed-citation xml:lang="ru">Laskowitz D.T., Bennett E.R., Durham R.J., et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: clinical outcomes from a phase i safety study // Stem Cells Transl Med. 2018. Vol. 7, N 7. P. 521–529. doi: 10.1002/sctm.18-0008</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Bleich D. Umbilical cord blood and type 1 diabetes: a road ahead or dead end? Diabetes Care. 2009;32(11):2138–2139. doi: 10.2337/dc09-1456</mixed-citation><mixed-citation xml:lang="ru">Bleich D. Umbilical cord blood and type 1 diabetes: a road ahead or dead end? // Diabetes Care. 2009. Vol. 32, N 11. P. 2138–2139. doi: 10.2337/dc09-1456</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Tyumina OV, Volchkov SE, Ovchinnikov PA. Primenenie gematopoeticheskikh stvolovykh kletok pupovinnoy krovi. Genes and Cells. 2019;14(3):236–237. (In Russ). doi: 10.23868/gc125543</mixed-citation><mixed-citation xml:lang="ru">Тюмина О.В., Волчков С.Е., Овчинников П.А. Применение гематопоэтических стволовых клеток пуповинной крови // Гены и клетки. 2019. Т. 14, № 3. С. 236–237. doi: 10.23868/gc125543</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Tyumina OV, Volchkov SE, Ovchinnikov PA, et al. Clinical evaluation of the efficiency of allogeneic cord blood transfusion in patients with autism. Genes and cells. 2020;15(3):74–79. (In Russ). doi: 10.23868/202011012</mixed-citation><mixed-citation xml:lang="ru">Тюмина О.В., Волчков С.Е., Овчинников П.А., и др. Оценка безопасности и эффективности метода трансфузии аллогенных гемопоэтических клеток пуповинной крови пациентам с расстройством аутистического спектра // Гены и клетки. 2020. Т. 15, № 3. С. 74–79. doi: 10.23868/202011012</mixed-citation></citation-alternatives></ref></ref-list></back></article>
